Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2025 –2032 | |
|
|
USD 2.45 Billion |
| USD 4.00 Billion | |
| % | |
|
Europe Pharmaceutical Excipients Market Segmentation, By Functionality (Binders and Adhesives, Disintegrants, Coating Material, Coloring Agents, Solubilizers, Flavors, Sweetening Agents, Diluents, Lubricants, Buffers, Emulsifying Agents, Preservatives, Antioxidants, Sorbents, Solvents, Emollients, Glidents, Chelating Agents, Antifoaming Agents, and Others), Dosage Form (Solid, Semi-Solid, Liquid), Route of Administration (Oral Excipients, Topical Excipients, Parenteral Excipients, and Other Excipients), End User (Pharmaceutical and Biopharmaceutical Companies, Contract Formulators, Research Organization and Academics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2032
Get Exclusive Sample Copy of this Report Here
|
Attributes
|
Pharmaceutical Excipients Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
Europe
|
|
Key Market Players
|
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, pricing analysis, brand share analysis, consumer survey, demography analysis, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.
|
Enhanced Efficiency Through Advanced Formulation and Digital Integration
Driver
Growing Need Due to Rising Demand for Advanced Drug Formulations
Restraint/Challenge
Concerns Regarding High Costs and Regulatory Compliance
The market is segmented on the basis of functionality, dosage form, route of administration, end user, and distribution channel
On the basis of functionality, the Europe pharmaceutical excipients market is segmented into binders and adhesives, disintegrants, coating material, coloring agents, solubilizers, flavors, sweetening agents, diluents, lubricants, buffers, emulsifying agents, preservatives, antioxidants, sorbents, solvents, emollients, glidents, chelating agents, antifoaming agents, and others. The binders and adhesives segment dominated the Europe Pharmaceutical Excipients market in 2024, accounting for 28.4% of total revenue. These excipients are essential in tablet and capsule formulations, ensuring structural integrity and improved compressibility. They enhance drug stability and help maintain consistent release profiles. Widely used in both large-scale pharmaceutical manufacturing and contract formulation, binders and adhesives provide reliability and multifunctional benefits. Their compatibility with multiple dosage forms makes them indispensable for modern drug production. Pharmaceutical manufacturers increasingly prefer binders that also support solubility and bioavailability improvements.
The coating material segment is expected to witness the fastest CAGR of 9.2% from 2025 to 2032, driven by rising demand for taste masking, extended-release formulations, and patient-friendly oral dosage forms. Coating materials improve stability, enhance aesthetic appeal, and reduce gastrointestinal irritation. They are particularly important in pediatric and geriatric formulations. Increasing regulatory approvals for novel polymers and enteric coatings further boost adoption. Pharmaceutical companies are investing in innovative coatings to differentiate products. Continuous R&D and optimization of coating excipients enhance drug performance. The growth is also fueled by demand for multifunctional coatings that contribute to solubility and controlled-release properties.
On the basis of dosage form, the Europe pharmaceutical excipients market is segmented into solid, semi-solid, and liquid. The solid dosage form segment dominated the Europe market in 2024, capturing 51.7% revenue share. Solid excipients are used extensively in tablets, capsules, and granules, providing precise dosing, long shelf life, and high stability. Their ease of manufacturing and scalability make them highly preferred in both generic and innovative drug production. Solid excipients improve compressibility and enable controlled drug release. Manufacturers rely on them for consistent quality across large production batches. They are compatible with advanced formulation technologies, including modified-release and multiparticulate systems. Solid excipients remain central to pharmaceutical manufacturing in Europe. The segment benefits from high demand across both hospitals and contract formulators.
The liquid dosage form segment is expected to register the fastest CAGR of 8.5% from 2025 to 2032, driven by oral suspensions, syrups, and parenteral solutions. Liquid excipients enhance solubility, stability, and bioavailability, improving patient compliance. Pediatric and geriatric formulations particularly rely on liquid excipients for palatability and ease of administration. Their integration with multifunctional excipients allows development of stable, effective, and patient-friendly products. Growing adoption of ready-to-use liquid drugs fuels growth. The segment also benefits from increasing clinical research and small-scale formulation activities. Expansion in contract manufacturing further supports rapid adoption across Europe.
On the basis of route of administration, the Europe pharmaceutical excipients market is segmented into oral excipients, topical excipients, parenteral excipients, and other excipients. The oral excipients subsegment dominated in 2024, accounting for 62.3% of total revenue, driven by the prevalence of oral drug delivery. Oral excipients are critical for tablets, capsules, and granules, improving taste, solubility, and stability. They enhance patient compliance and are compatible with various drug release profiles. Pharmaceutical companies prefer oral excipients due to ease of formulation and regulatory familiarity. Increasing demand for pediatric and geriatric oral medications strengthens adoption. Oral excipients remain central to both generic and innovative drug pipelines. Their reliability and versatility make them a primary revenue contributor. Growing investments in patient-centric formulations further reinforce this dominance.
Parenteral excipients are expected to witness the fastest CAGR of 10.1% from 2025 to 2032, fueled by growth in injectable biologics, vaccines, and advanced parenteral therapies. These excipients improve solubility, stability, and sterility of injectable drugs. Increasing adoption of protein- and peptide-based therapeutics accelerates demand. Parenteral excipients ensure precise dosing and extended shelf life. Rising biologics manufacturing in Europe further drives growth. They are crucial for sterile formulation compliance and regulatory adherence. Continuous R&D investment in parenteral solutions supports rapid adoption. The segment benefits from increasing clinical trials and specialized formulation needs.
On the basis of end user, the Europe pharmaceutical excipients market is segmented into pharmaceutical and biopharmaceutical companies, contract formulators, research organizations and academics, and others. Pharmaceutical and biopharmaceutical companies dominated the market in 2024, holding 58.6% of total revenue. Their dominance is driven by large-scale manufacturing, continuous R&D, and high-volume excipient requirements. They rely on multifunctional excipients to optimize formulations and ensure stability. Partnerships with suppliers enhance supply chain efficiency. The segment supports both generic and innovative drug production. High demand for patient-centric, controlled-release, and complex formulations strengthens this subsegment. Pharmaceutical companies’ regulatory expertise ensures consistent adoption. The dominance is reinforced by ongoing investments in advanced excipients.
Contract formulators are expected to witness the fastest CAGR of 9.6% from 2025 to 2032, driven by outsourcing trends and specialized formulation demand. They depend on advanced excipients to meet client-specific requirements efficiently. Growth is fueled by small and mid-sized pharmaceutical companies outsourcing drug development. Adoption of complex oral, parenteral, and topical formulations accelerates demand. The segment benefits from flexibility and regulatory compliance expertise. Collaborative initiatives with excipient suppliers enhance rapid uptake. Rising clinical trials and pilot-scale production further support growth. The segment is expanding across Europe due to increasing R&D and formulation outsourcing.
On the basis of distribution channel, the Europe pharmaceutical excipients market is segmented into direct tender, retail sales, and others. Direct tender dominated the market in 2024, accounting for 46.2% of total revenue, driven by bulk procurement by pharmaceutical manufacturers and hospitals. This channel ensures cost efficiency, regulatory compliance, and uninterrupted supply. Long-term contracts and personalized supplier support strengthen adoption. High-volume purchases of critical excipients rely on this channel. Manufacturers can customize formulations and maintain supply chain reliability. It is particularly preferred by large-scale production facilities. Strong supplier relationships reinforce trust and continuous revenue contribution. Direct tender remains the primary procurement method across Europe.
Retail sales are expected to witness the fastest CAGR of 8.9% from 2025 to 2032, driven by small and medium pharmaceutical companies, contract formulators, and research organizations. Retail distribution provides access to smaller quantities of specialty excipients. E-commerce platforms and specialized distributors improve procurement efficiency. The segment supports pilot-scale production, R&D, and clinical trial requirements. Quick availability and convenience encourage adoption. Retail sales facilitate experimentation with novel excipients and formulations. Rising research activities across Europe further accelerate growth. The segment is increasingly relevant for customized and niche excipient needs.
Germany Pharmaceutical Excipients Market Insight
The Germany pharmaceutical excipients market emerged as the dominant country in the European market in 2024, capturing the largest revenue share of 38.7%. This strong market position is supported by the country’s advanced pharmaceutical manufacturing capabilities, a robust research and development ecosystem, and the widespread integration of innovative excipients in drug formulations. Furthermore, the presence of leading pharmaceutical companies and substantial investments in clean-label and plant-based excipients reinforce Germany’s market leadership, enabling the country to maintain a competitive edge in the European market.
France Pharmaceutical Excipients Market Insight
The France pharmaceutical excipients market is projected to be the fastest-growing country in the European market during the forecast period, registering the highest CAGR of 9.1%. This impressive growth is driven by increasing investments in both nutraceutical and pharmaceutical research, rising demand for personalized medicine, and government initiatives aimed at promoting the development and utilization of fortified and functional drug formulations. The focus on innovation and the growing pharmaceutical infrastructure in France are expected to further accelerate market adoption of advanced excipients, positioning the country as a key growth hub in Europe.
The pharmaceutical excipients industry is primarily led by well-established companies, including:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.